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Background: Ovarian cancer remains an on-going challenge mainly due to the development of drug resistance
and also because the cancer is likely to have metastasized at the time of diagnosis. Currently, chemotherapy based
on platinum drugs such as cisplatin is the primary treatment for the disease. Copper transporter 1 is involved in the
transport of cisplatin into the cell, but is also down-regulated by the drug. Bortezomib, a proteasome inhibitor, has
been reported to block this platinum-induced down-regulation of CTR1, so that in the presence of bortezomib, the
cellular uptake of platinum drugs may be increased. Increased platinum accumulation may result in increased
platinum −DNA binding so that the platinum drug in combination with bortezomib may produce enhanced cell kill.
Methods: In this study the efficacy of the sequential combinations of carboplatin, oxaliplatin and a trans-platinum
compound coded as CH1 with BORT on the human ovarian A2780, A2780cisR, A2780ZD0473R and SKOV-3 cancer cell lines
was evaluated. The levels of cellular platinum accumulation and platinum-DNA binding were determined following the
treatment with these combinations. In order to investigate the effect of the combinations of the formation of ROS, the
total and oxidized glutathione levels were also determined.
Results: Prevention of copper transporter 1 degradation by bortezomib is found to enhance the cellular accumulation
of platinum, the level of Platinum−DNA binding and increases oxidative stress especially in the resistant cell lines.
Conclusions: The results suggest that the prevention of CTR1 degradation by bortezomib may be playing a major role
in increasing the cellular uptake of platinum drugs and platinum-DNA binding level. Furthermore, the generation of
oxidative stress appears to be a major contributor to the enhanced cell kill.
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Proteasomal degradationBackground
Although platinum drugs cisplatin (CS), carboplatin (CB)
and oxaliplatin (OX) are widely used alone and in combin-
ation with other drugs such as paclitaxel for treatment the
of various cancers [1], their use has been limited due to
dose-limiting toxicities, and intrinsic and/or acquired re-
sistance leading to treatment failure [2]. Decreased cellular
accumulation due to reduced drug intake and/or increased
efflux [3-5], increased inactivation due to binding with
glutathione or metallothionein, enhanced tolerance to* Correspondence: fazlul.huq@sydney.edu.au
1Cumberland Campus, The University of Sydney, Lidcombe, Sydney, NSW
2141, Australia
Full list of author information is available at the end of the article
© 2013 Al-Eisawi et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the orplatinum −DNA adducts and increased DNA repair are
considered to be amongst the predominant mechanisms
of resistance to platinum drugs [2,4].
In line with the idea that copper transporter 1 (CTR1)
is a carrier for CS into the cell [6-10], it has been found
that platinum accumulation in CTR1 knockout mice is
markedly reduced [11] and its over-expression enhances
the uptake [12,13]. Furthermore, the CS-resistant variant
of ovarian A2780 cancer cell line has been found to have
a reduced expression of hCTR1 mRNA. These results
strongly suggest that efficacy due to platinum-based che-
motherapy may be significantly improved through the
modulation of CTR1 expression. It is important to note
that like CTR1 that acts as the input carrier for Cu andal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diate both Cu and Pt efflux out of the cell [3,6,14].
Howell and co-workers have demonstrated that although
CS is transported into the cell by CTR1, the drug triggers
the proteasomal degradation of the carrier thereby limiting
its own uptake [15], a process that can be prevented by
pretreatment of cells with proteasomal inhibitors such as
MG-132, lactacystin and bortezomib (BORT) [15,16]. An
exception is the CTR1 expressed in human embryonic kid-
ney cells that is not subject to CS-induced degradation, be-
ing stabilized as a multimeric complex [17]. Our recent
studies have also confirmed that an increase in cell kill
resulting from the combination of CS with BORT in ovar-
ian tumour models is associated with an increase in cellu-
lar accumulation of CS and the level of Pt −DNA binding
[18].
Proteasome inhibition represents a unique approach
to anticancer therapy as it targets the key regulator of
intracellular protein degradation. In vitro studies haveFigure 1 Simplified representation of cellular events responsible for a
in which DNA damage, ER stress and increase in ROS due to platinum
by bortezomib lead to apoptosis. L1 and L2 denote the carrier ligands a
which has a trans-geometry, L1 and L4 represent the carrier ligands and L2shown that the inhibition of the proteasome leads to
the accumulation of inhibitor of κB (IκB) causing the
down-regulation of the anti-apoptotic transcription fac-
tor NF-κB [19]. It also causes down regulation of other
anti-apoptotic proteins such as MCL1, IAP and up re-
gulation of pro-apoptotic proteins such as NOXA, p53,
p27, BAX, BIM and SMAC [20]. Thus proteasome in-
hibition due to treatment with BORT can cause a shift
in the balance between pro-apoptotic and anti-apoptotic
factors towards apoptotic cell death, besides preventing
the degradation of CTR1. BORT can also cause the pro-
duction of reactive oxygen species (ROS) resulting into
oxidative stress that further enhances the induction of
apoptosis [21,22] (Figure 1).
Human hCTR1 contains two methionine-rich motifs
(hCTR1 Met) and two histidine-rich motifs (hCRT1 His)
on its extracellular N-terminus that are thought to be
essential for the function of the transporter. It has been
shown that the interaction of CS, CB and OX withpoptosis due to combination of platinum drugs and bortezomib
drugs and inactivation of antiapoptotic proteins such as NF-kB
nd L3 and L4 denote the leaving groups in CS, CB and OX. In CH1
and L3 represent the leaving groups.
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that contain three or more methionines result in the
removal of the carrier ligands in the case of CS and CB
[23] whereas OX is found to retain its DACH moiety
(Figure 2). Recent studies by Wang et al. based on
NMR spectroscopy and electrospray ionization mass
spectrometry show that a maximum of two Pt atoms are
bound to each monomer unit of hCTR1 for CB as well
as for CS [24]. The binding to extracellular domain ra-
ther tight fit into any small pocket present in the carrier,
leaves the door open for hCTR1 to serve as the influx
carrier for larger platinum compounds such as OX,
trans-planaramineplatinum(II) CH1 [25] and even poly-
nuclear platinums such as BBR3464 and DH6Cl [26,27].
The present study aimed to determine the efficacy of
sequential combinations of CB, OX and a trans-planara-
mineplatinum(II) coded as CH1 with BORT in ovarian
tumour models [28].
Methods
CB and OX were purchased from Sigma Aldrich, Sydney,
Australia. BORT was purchased from LC Laboratories
Woburn, MA, USA. The Trans-bis(3-hydroxypyridine)
dichloroplatinum(II) coded as CH1 was synthesized in the
host laboratory as described by Chowdhury et al. [25].
Foetal calf serum (FCS), RPMI-1640, 200 mM L-glutamine,
and 5.6% sodium bicarbonate were purchased from Trace
Biosciences Pty Ltd Australia. The DNA extraction kit JET-
QUICK Blood DNA Spin Kit/50 was obtained from Astral
Scientific Pty Ltd, Sydney, Australia. GSH/GSSG-Glo™
















Figure 2 Chemical structures of platinum compounds carboplatin (CB
(II) (CH1), and that of proteasome inhibitor bortezomib (BORT), applieAll other chemicals were obtained from Sigma-Aldrich,
Sydney, Australia. A2780, A2780cisR, A2780ZD0473R and
SKOV-3 ovarian cancer cell lines were gifts from Ms. Mei
Zhang, Royal Prince Alfred Hospital, Sydney, Australia.
Stock solutions (1 mM) of CB and OX were prepared in
mQ water, that of CH1 prepared in 1:4 DMF to mQ water
and that of BORT was made in ethanol. The solutions
were sterilised by filtration.
Cell culture
Human ovarian cancer cell lines A2780, A2780cisR,
A2780ZD0473R and SKOV-3 (Table 1) were seeded in
25 cm2 tissue culture flasks in a humidified atmosphere
consisting of 5% CO2 and 95% air at 37°C. The cells in
logarithmic growth phase were maintained in complete
medium consisting of RPMI 1640, 10% heat inactivated
FCS, 20 mM Hepes, 0.11% bicarbonate, and 2 mM glu-
tamine without antibiotics. Each cell line was seeded in
10% FCS/RPMI 1640 culture medium at a density of
4000 and 5500 cells/well in flat-bottomed 96-well cul-
ture plate. The plate was then incubated for 24 h at 37°C
in a humidified atmosphere to allow the cells to attach.
Single-drug treatment
Stock solutions of CB, OX, CH1 and BORT were sub-
jected to serial dilutions to give final concentrations
ranging from 0.0008 to 250 μM, made. The dilutions
were made using 10% RMPI-1640 medium without
serum and were added to equal volumes of cell culture
in triplicate wells. Cells were treated with the drugs



















), oxaliplatin (OX), trans-bis(3-hydroxypyridine)dichloroplatinum
d in combination to ovarian cancer cell lines.
Table 1 Human ovarian cancer cell lines used in this
study
Cell line Phenotype
A2780 Untreated ovarian tumour
A2780cisR CS resistant ovarian tumour
A2780ZD0473R ZD0473 resistant ovarian tumour
SKOV3 Estrogen receptor positive ovarian tumour
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(IC50) values i.e. drug concentrations required for 50%
cell kill.
Combination studies
Cells were treated with CB, OX, CH1 and BORT alone
and in combinations (CB + BORT, OX + BORT and
CH1 + BORT) at three different concentration. Three
modes of administration: 0/0 h, 0/2 h and 2/0 h were
used, where 0/0 h indicates that both the compounds
were added simultaneously, 0/2 h means that the
platinum drug was added first followed by BORT 2 h
later and 2/0 h means that the platinum drug was added
2 h after the addition of BORT. The period of drug
treatment was 72 h counted from the time of addition
ofthe first compound. Cell growth inhibition was deter-
mined using the MTT reduction assay. Combination
index values (CIs) were used as measures of synergism,
additiveness or antagonism calculated using the pro-
gram CalcuSyn [29-31]. The CI for binary combinations





Where D1 and D2 respectively represent mean doses
of compounds 1 and 2 in combination required to
cause x% inhibition, whereas D1× and D2× represent the
doses of compounds 1 and 2 respectively required to
cause x% inhibition when present alone. Dx is calcu-
lated from the following median effect equation, where
Dx denotes the dose of drug, Dm is the median-effect
dose, fa is the fraction of cells affected so that fu = 1-fa
and m is the exponent defining the shape of the dose
effect curve. CI values of <1, =1 and >1 indicate syner-
gism, additivity and antagonism in combined drug ac-
tion, respectively.
D ¼ DmX fa= 1‐fað Þ½ 1=m
Platinum cellular accumulation and platinum −DNA
binding studies
The cellular accumulation of platinum and platinum −
DNA binding levels from the 0/0 h and 0/2 h combinationsof CB and OX with BORT in A2780 and A2780cisR cell
lines were determined. Combinations of the drugs at their
IC50 values were added to culture plates containing expo-
nentially growing A2780 and A2780cisR cells in 10 mL 10%
FCS/RPMI 1640 culture medium with cell density of
5 × 106 cells mL–1 and incubated for 24 h. The cells were
scraped off the culture plates and transferred to 10 mL
centrifuge tubes and spun at 3500 rpm for 2 min at 4°C.
The cells were washed thrice with ice-cold phosphate-
buffered saline (PBS) and the pellets were stored at −20°C
until assayed. A minimum of three independent experi-
ments were performed.
Cellular accumulation
Following drug treatments and collection, the cell pellets
were resuspended in 0.5 mL 1% triton-X and sonicated
for 30 min on ice. The total intracellular content of plat-
inum was determined by graphite furnace atomic ab-
sorption spectrophotometry.
Platinum–DNA binding
The DNA isolated from cell pellets using JETQUICK
Blood DNA Spin Kit/50 Astral Scientific Pty Ltd were
analysed for it platinum bound content by graphite fur-
nace AAS. A260/A280 nm ratios were between 1.75 and
1.8 for all samples indicating high purity of the DNA.
Cellular glutathione
As a measure of the redox state of the cells, the levels of
total glutathione (GSH and GSSG) as well as oxidised
glutathione (GSSG) in A2780 and A2780cisR cell lines
were determined for the 0/0 h and 0/2 h sequenced
combinations of CB and OX with BORT. Drugs made in
10% RMPI-1640 serum free medium were added to
equal volumes of cell culture wells of a white wall clear
bottom 94 well plate containing exponentially growing
A2780 and A2780cisR cells (cell density = 12 × 103 cells/
well). Cells were left to incubate for 24 h. The media
was aspirated out of the treatment wells with minimal
disturbance of the cell pellets and cells were washed
with 200 μL of PBS following which the levels of gluta-
thione were determined using the GSH/GSSG-Glo™
Assay kit (Promega). The plate was read in a LUMIstar
Omega luminometer (BMG LABTECH, USA).
Results
Cytotoxicity
Figure 3 shows the cell survival fraction versus concen-
tration plots for CB, OX, CH1 and BORT as applied to
the human ovarian cancer cell line A2780, A2780cisR,
A2780ZD0473R and SKOV-3. The parent A2780 cell line
was most sensitive to the drugs. A2780ZD0473R was the
most resistant to CB whereas SKOV-3 was the most re-



























































































Figure 3 Inhibition of cell growth as a function of increasing concentrations of a) CB, b) OX c) CH1 and d) BORT as applied to the
ovarian cancer cell lines A2780, A2780cisR, A2780ZD0473R and SKOV-3. Cell survival fractions following treatment with increasing
concentrations of drugs for 72 h were determined using MTT assay and spectrophotometric analysis. Error bars represent the standard deviation.
Al-Eisawi et al. Journal of Ovarian Research 2013, 6:78 Page 5 of 11
http://www.ovarianresearch.com/content/6/1/78compounds against the cell lines are presented in
Table 2. The IC50 values for CB and OX are found to be
greater in the resistant A2780cisR, A2780ZD0473R and
SKOV-3 cell lines with OX having very high value in
SKOV-3. The activity of CH1 on the other hand is
found to be comparable against all the cell lines so thatTable 2 Summary of the IC50 values (μM) and Resistance Fact
ovarian cancer cell lines A2780, A2780cisR, A2780ZD0473R and
A2780 A2780cisR RF
CS 0.5 ± 0.03 8.2 ± 0.6 17.7
CB 14.0 ± 1.4 48.9 ± 3.9 3.5
OX 0.2 ± 0.01 0.4 ± 0.02 1.9
CH1 21.3 ± 2.0 26.6 ± 1.9 1.2
BORT 0.05 ± 0.01 0.05 ± 0.01 1.0
RF is defined as the ratio of the IC50 value in the resistant cell line over that in the rit has the lowest resistance factors as compared to CB
and OX. The IC50 values for BORT against A2780
cisR
and A2780ZD0473R are found to be nearly the same as
that against the parent A2780 cell line and slightly
greater against SKOV-3 cell line. Furthermore, BORT is
found to be significantly more active than CB, OX andors (RF) for CS, CB, OX, CH1 and BORT as applied to the
SKOV-3
A2780ZD0473R RF SKOV-3 RF
6.0 ± 0.5 13.0 10.2 ± 0.5 22.2
64.6 ± 3.2 4.6 43.4 ± 3.9 3.1
0.4 ± 0.03 2.1 43.6 ± 3.0 229.4
25.4 ± 1.7 1.2 29.8 ± 1.8 1.4
0.04 ± 0.01 0.8 0.09 ± 0.01 1.8

























































A2780           A2780cisR A2780ZD0473R  SKOV-3
-----------------------------------------------------------------------------------------------------------
Figure 4 Combination Index (CI) values applying to the
sequenced combinations of a) CB, b) OX and c) CH1 with BORT
administered to the ovarian A2780, A2780cisR, A2780ZD0473R
and SKOV-3 cancer cell lines. CI values were calculated following
72 h treatments with the drugs at their equipotent ratios. CI values
of <1, =1 and >1 indicate respectively synergism, additivity and
antagonism in combined drug action.
Al-Eisawi et al. Journal of Ovarian Research 2013, 6:78 Page 6 of 11
http://www.ovarianresearch.com/content/6/1/78CH1 against all four human ovarian cancer cell lines.
This work does not require any ethical approval as it
does not involve animals and humans.
Combination studies
Figure 4 a, b, c and d show respectively the combination
index values [32] for the combinations of CB, OX and
CH1 with BORT in: A2780, A2780cisR, A2780ZD0473R and
SKOV-3 cell lines. Combinations of CB with BORT were
found to be synergistic in A2780, A2780ZD0473R and
SKOV-3 cell lines irrespective of the sequence of adminis-
tration with the greatest cell kill resulting from the 0/2 h
sequence. In the CS resistant cell line A2780cisR, all combi-
nations of CB and BORT produced pronounced cell death.
The SKOV-3 cell line also responded well to the combin-
ation of OX with BORT with greatest synergism being ob-
served with the 0/2 h sequence of administration. The
bolus administration of OX and BORT resulted in syner-
gism in A2780 whereas 0/2 h and 2/0 h sequences of ad-
ministration were slightly antagonistic. On the other hand,
the bolus and 2/0 h sequence of combinations of OX with
BORT caused synergism in A2780ZD0473R cell line while
0/2 h sequence of administration was found to be antag-
onistic. The combinations of the trans-platinum CH1 with
BORT were also found to be synergistic in A2780ZD0473R,
SKOV-3 and A2780cisR cells except for the 0/2 h sequence
of administration in A2780cisR. The 0/2 h sequence of
administration was also antagonistic in the parent A2780
cell line.
Platinum accumulation
To determine whether the presence of BORT led to an en-
hancement in the uptake of CB and OX, the level of intra-
cellular platinum in A2780 and A2780cisR, A2780ZD0473R
and SKOV-3 cell lines were determined after 24 h treat-
ment for each drug combination (Figure 5). It was found
that the intracellular accumulation of platinum from CB
alone was greater in the parent A2780 cell line than in the
resistant A2780cisR cell line whereas the converse was true
from OX. Also the presence of BORT was found to in-
crease the accumulation of CB in the resistant A2780cisR
cell line (but not in the parent A2780 cell line) for both
0/0 h and 2/0 h sequences of administration (more so for
the 2/0 h sequence of administration). The presence of
BORT was also found to increase cellular accumulation of
CB in SKOV-3 cell line but more so for the 0/0 h se-
quence of administration than 2/0 h sequence of adminis-
tration. The presence of BORT was not found to have
significant on cellular of CB in A2780ZD047R cell line. As
applied to the parent A2780 cell line, on face value, served
to decrease rather than increase the cellular accumulation
of CB although uncertainty remains because of large error.
A further point to note that increase in accumulation of
CB in A2780cisR cell line, did not result in any increase inthe cell kill. The cellular accumulation of OX was found
to be highest in the resistant A2780cisR cell line but lower





































































Figure 5 Cellular platinum accumulation in ovarian cancer A2780 and A2780cisR, A2780ZD0473R and SKOV-3 cell lines as applied to
single treatments of CB and OX and their selected combinations with BORT. Cells were treated with the drugs for 24 h followed by
collection, lysis and finally the detection of Pt was using AAS. Data were statistically analyzed using the paired Student’s t test: * p <0.05 indicates
significant difference from control. Error bars represent the standard deviation.
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istration resulted in highest platinum accumulation in the
resistant A2780cisR cell line whereas 2/0 h sequence of ad-
ministration resulted in highest platinum accumulation in
the parent A2780 cell line.
Platinum −DNA binding
As the action of platinum drugs is associated with their





























Figure 6 Platinum −DNA binding levels in the ovarian A2780, A2780c
with CB and OX and their combinations with BORT. Cells were treated
finally the detection of Pt using AAS. Data were statistically analyzed using
from control. Error bars represent the standard deviation.A2780 and A2780cisR, A2780ZD0473R and SKOV-3 cell lines
were determined for the 0/0 h and 2/0 h combinations of
CB and OX with BORT. Figure 6 shows the platinum −
DNA binding levels in A2780 and A2780cisR, A2780ZD0473R
and SKOV-3 cell lines resulting from CB and OX alone and
from the 0/0 h and 2/0 h combinations of CB and OX with
BORT. Platinum −DNA binding level from CB alone was
found to be highest in the resistant A2780cisR cell line and



































isR, A2780ZD0473R and SKOV-3 cancer cell lines due to treatment
with the drugs for 24 h followed by collection, DNA extraction and
the paired Student’s t test: * p <0.05 indicates significant difference
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of CB and OX with BORT were found to be greater than
those from CB and OX alone in both the parent A2780
and the resistant A2780cisR cell lines. The levels in
A2780ZD047R and SKOV-3 cell lines were found to be
much lower from the drugs alone as well as their combi-
nations with BORT. A more careful analysis shows that
0/0 h combination of CB with BORT resulted in a sig-
nificant increase in platinum −DNA binding level in
both A2780ZD047R and SKOV-3 cell lines. As applied to
combination of OX with BORT, both the sequences of
administration resulted in increase in platinum −DNA
binding in all the four cell lines A2780, A2780cisR,
A2780ZD047R and SKOV-3.
Cellular glutathione
As both platinum drugs and BORT are able to induce
oxidative stress in the cells that may also lead to apop-
tosis, the effect of the drug combination on cellular
glutathione levels was investigated. Figures 7 a and b
show the levels of total glutathione (GSH and GSSG)
and oxidized glutathione (GSSG) (in relative lumines-
cence units) in A2780, A2780cisR and SKOV-3 cell lines
after treatment of cells with combinations of BORT
with CB and OX, administered using 0/0 h and 0/2 h
sequences. The level of glutathione in A2780ZD0473R
cell line was not determined to minimise cost. Table 3
gives the ratios of GSH/GSSG before and after treat-
ments with BORT and its combinations with CB and
OX.
Both total and oxidised glutathione levels were found
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Figure 7 Levels of reduced (GSH) and oxidized (GSSG) forms of cellul
and after treatments with BORT alone and its combination with CB an
lines. Cells were treated for 24 h and glutathione content was determined
the paired Student’s t test: * p <0.05 indicates significant difference from colowest in the parent A2780 cell line. Treatment with
BORT alone also caused a significant decrease in GSH
level in A2780, A2780cisR and SKOV-3 cell lines, thus
indicating the heightening of oxidative stress.
It can be seen that treatments with BORTand its combi-
nations with CB and OX have served to decrease values
for GSH/GSSG ratio relative to the control – more so in
the resistant A2780cisR and SKOV-3 cell lines than in the
parent A2780 cell line.
Discussion
In this study, efficacy of sequenced combinations of CB,
OX and CH1 with proteasome inhibitor BORT in human
ovarian A2780, A2780cisR, A2780ZD0473R and SKOV-3 cell
lines was determined, as differences in mechanism of action
suggest that the drugs might act synergistically in combin-
ation. Besides being a highly potent anticancer drug on its
own right, BORT can also enhance the activity of platinum
drugs by counteracting platinum-induced loss of CTR1 ex-
pression [16]. Amongst the three platinum compounds,
OX was most active and CH1 was least active against the
parent cell line A2780. CB was the least active compound
against the resistant A2780cisR and A2780ZD0473R cell lines.
Although both CB and CS form intrastrand bifunctional
adducts with DNA (that are followed by protein recogni-
tion and cascade of events leading to programmed cell
death), the two compounds differ in their leaving groups
(chloride in CS and cyclobutanedicarboxylate (CBDCA) lig-
and in CB) and consequently in their reactivity. The ligand
exchange reactions with carboxylate groups are much
slower than those with the chloride ligand so that CB is sig-
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ar glutathione in relative luminescence units (RLU × 105) before
d OX in the ovarian cancer A2780, A2780cisR and SKOV-3 cell
using GSH/GSSG-Glo Assay kit. Data were statistically analyzed using
ntrol. Error bars represent the standard deviation.
Table 3 Ratios of GSH/GSSG before and after treatments
with BORT and its combinations with CB and OX in
A2780, A2780cisR and SKOV-3 ovarian cancer cell lines
A2780 A2780cisR SKOV-3
Control 241.32 40.2 38.00
BORT 31.3 14.7 42.56
CB + BORT (0/2 h) 78.35 13.1 38.53
CB + BORT (2/0 h) 50.27 13.8 35.70
OX + BORT (0/2 h) 71.77 39.25 38.16
OX + BORT (2/0 h) 69.97 33.31 43.74
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the CBDCA ring and that the rate of ring opening is
strongly dependent on the availability of nucleophiles, espe-
cially sulfur-containing ones [34]. The lower reactivity of
CB relative to CS, serves to lengthen the time required for
its aquation and subsequent formation of adducts with
DNA [35]. Consequently, CB is 4- to 10-fold less potent
than CS in various tumour cell types as evident from differ-
ences in IC50 values of the two compounds [33]. However,
tumour cell lines resistant to CS have been found to be
cross-resistant to CB, a fact that has been attributed to the
formation of identical adducts with DNA [36].
Much greater activity of OX than CS against A2780,
A2780cisR and A2780ZD0473R cell lines may be due to dif-
ferences in their structures in terms of both the leaving
groups (oxalate in OX as against Cl- in CS) and the car-
rier ligands (trans-R,R-diaminocyclohexane abbreviated
as DACH present in OX as against NH3 in CS). Al-
though OX, having a cis-geometry like CS, can form
intrastrand 1,2-(GpG) adducts with DNA, several con-
formational differences exist in the intrastrand
1,2-(GpG) adducts formed by CS and OX [37,38]. These
conformational differences may be responsible for dif-
ferences in protein recognition and cellular processing,
thus providing an explanation (at least in part) as to
why OX–DNA adducts are not recognized by mismatch
repair proteins so that OX has a higher activity than CS
in CS-resistant tumours [39]. Much lower activity of
OX against SKOV-3 cell line may be due to p53-null
status of the cells. Mutations of p53 in cancer cells in-
variably abolish its activity, due to the pro-apoptotic
role played by p53 in tumour suppression [40]. In a
panel of colon cancer cell lines, sensitivity to OX was
found to be characteristic of p53 wild-type cells whereas
p53 mutated-cells exhibited a marked increase in resist-
ance to OX [41]. Further work needs to be carried out to
fully elucidate the mechanisms of resistance in SKOV-3
against OX. Although the trans-platinum compound
CH1 has a relatively lower activity than cis-platinums
against all four ovarian cancer cell lines, it has lower re-
sistance factors, indicating that at the level of its activity
CH1 has been better able to overcome mechanisms ofresistance operating in A2780cisR, A2780ZD0473R and
SKOV-3 cell lines.
BORT has shown remarkably high activity against all
the four human ovarian cancer cell lines. Inhibition of
proteasome leads to the up-regulation of pro-apoptotic
proteins such as inhibitor of κB (IκB), p53 and NOXA
and down-regulation of anti-apoptotic proteins such as
MCL1, IAP [19,20], thus enabling BORT to induce
apoptosis independent of platinum action (in terms of
binding to the DNA).
Combinations of CB with BORT were found to be syn-
ergistic in A2780, A2780ZD0473R and SKOV-3 cell lines ir-
respective of sequence of administration but antagonistic
in A2780cisR cell line. The synergism in activity from 0/0 h
and 2/0 h combinations of CS with BORT in A2780 and
A2780cisR cell lines is in line with the increased cellular ac-
cumulation of platinum and increased level of Pt −DNA
binding. In a phase I clinical trial, the combination of CB
with BORT has shown promising results [42]. BORT de-
creased CB-induced NF-κB activity with 47% overall re-
sponse rates, two complete responses (CR) and five partial
responses, including one CR in a patient with platinum-
resistant disease [42]. In the present study, combinations
of CB with BORT were not found to cause any enhance-
ment of cell kill in the CS-resistant cell line (in actual fact
the combinations were antagonistic in action), although
both the cellular platinum accumulation of platinum and
the level of Pt −DNA binding were elevated in A2780 and
A2780cisR cell lines. It is likely that much higher activity of
BORT against both A2780 and A2780cisR cell lines but
much lower activity of CB against A2780cisR cell line than
the parent A2780 cell line, has served to dampen the effect
of increase in Pt −DNA level that results from the protect-
ive role played by BORTagainst CTR1 degradation. As ap-
plied to the combinations of BORT and OX also, both
cellular accumulation of platinum and the level of Pt −
DNA binding were found to be greater than those from
OX alone in both the cell lines. The increase in platinum
uptake and the level of Pt −DNA binding from OX in the
presence of BORT suggests that CTR1 can also serve as a
carrier for the much larger molecule OX. In the case
of the much larger molecule CH1, it appears that this
compound also acts synergistically in combination with
BORT in A2780cisR, A2780ZD0473R and SKOV-3 cell lines
(although not so in the parent A2780 cell line) suggesting
that BORT may be acting as a carrier for OX and CH1 as
well. This is not unexpected as the association between
CTR1 and platinum drugs does not involve tight fit into a
small pocket. Surprisingly, the SKOV-3 cell line that
showed marked resistance to OX was most responsive to
the combination of OX with BORT, indicating that the
presence of BORT had served to greatly sensitize the
SKOV-3 cells to cell kill due to OX. The cellular accumu-
lation of platinum from combinations of OX with BORT
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the four A2780, A2780cisR, A2780ZD0473R and SKOV-3 cell
lines as applied to the 0/0 h sequence of administration
and in A2780, A2780cisR and SKOV-3 cell lines as applied
to 2/0 h sequence of administration and the levels of
platinum −DNA binding are greater in A2780, A2780cisR,
A2780ZD0473R and SKOV-3 cell lines (more so in A2780
and A2780cisR cell lines ) for both 0/0 h and 2/0 h se-
quences of administration. The results can be seen to be
in line with synergistic nature of the combinations. Finally,
the results indicate the combinations of CB, OX and CH1
with BORT generally serve to enhance cell kill especially
in the resistant cell lines.
As BORT and platinum drugs are known to cause oxi-
dative stress in cancer cells, the level of cellular glutathi-
one was determined for the combinations of BORT with
CB and OX. It was found that the treatment of A2780,
A2780cisR and SKOV-3 ovarian cancer cells with BORT
alone and its combinations with CB and OX significantly
reduced the total glutathione (GSH and GSSG) levels in
all the three cell lines – more so from BORT alone than
from the combinations. The results indicate that the
proteasome inhibitor BORT induces a greater oxidative
stress in cancer cells than platinum drugs CB and OX
although all the three compounds − BORT, CB and OX
− can induce oxidative stress in the cells. The change
was found to be more significant for the reduced form
GSH than the oxidized form GSSG so that treatments
with BORT and its combinations with CB and OX
have served to decrease the values for GSH/GSSG ratio
(relative to the control) and more so in the resistant
A2780cisR and SKOV-3 cell lines than in the parent
A2780 cell line. The results indicate that treatment of
the cells with BORT and its combinations with CB and
OX have served to heighten oxidative stress in the cells.
Contrary to the common observation that the oxidised
form of glutathione (GSSG) is elevated following oxida-
tive stress, in the present study it was found that the
level of GSSG decreased (although only slightly) after
the drug treatments. It is important to note that GSSG
may either recycle to GSH or exit from the cells, leading
to the overall depletion of cellular glutathione content
[43]. The fact that both reduced and oxidised forms of
glutathione decreased following drug treatment means
that it is more likely that the extrusion of glutathione
has occurred, possibly through the multidrug resistance-
associated protein (MRP) [44].
In summary, the key points in regard to the combina-
tions of platinum drugs and BORT administered to ovar-
ian tumour models are: i. Proteasomal degradation of
CTR1 induced by CS and possibly by other platinum
drugs so that CS serves to decrease its own uptake, ii.
BORT plays a protective role against CS-induced protea-
somal degradation of CTR1 so that in presence of BORTcellular accumulation of platinum and the level of
platinum-DNA binding is enhanced, iii. Protein recogni-
tion of platinum −DNA lesions may initiate a cascade of
events leading to apoptosis or repair of the DNA lesions
causing drug resistance, iv. BORT causes death of cancer
cells through proteasome inhibition, v. both platinum
drugs and BORT cause apoptosis through oxidative
stress, and vi. the much greater activity of BORT as
compared to platinum drugs, especially in the resistant
tumour models, masks the effects of CTR1-prtoection.
Figure 1 gives a pictorial representation of key events as-
sociated with the combination of platinum drugs with
BORT administered to ovarian cancer cells.
Conclusion
The increase in cellular accumulation of platinum and the
level of Pt −DNA binding associated with combination of
BORT with CB and OX in ovarian tumour models indi-
cate that BORT may serve to protect CTR1 from CS-
induced proteasomal degradation. However, the effect on
the cell kill appears to be less significant due to much
lower activity of platinum drugs as compared to BORT.
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